Table 3:

Relative risk of ischemic stroke, by α-blocker

Period^*	Terazosin		Doxazosin		Doxazosin-XL		Tamsulosin		Alfuzosin

	Unadjusted IRR (95% CI)	Adjusted IRR^† (95% CI)	Unadjusted IRR (95% CI)	Adjusted IRR^† (95% CI)	Unadjusted IRR (95% CI)	Adjusted IRR^† (95% CI)	Unadjusted IRR (95% CI)	Adjusted IRR^† (95% CI)	Unadjusted IRR (95% CI)	Adjusted IRR^† (95% CI)
Unexposed (ref)	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00

Pre-exposure

Risk period 2 (−22 to −60 d)	1.77 (1.45–2.15)	1.80 (1.48–2.20)	1.92 (1.57–2.35)	1.95 (1.59–2.38)	2.56 (1.98–3.31)	2.59 (2.00–3.35)	2.00 (1.74–2.30)	2.04 (1.77–2.34)	1.55 (1.05–2.29)	1.58 (1.07–2.34)

Risk period 1 (−1 to −21 d)	2.80 (2.27–3.45)	2.85 (2.31–3.52)	2.55 (2.03–3.20)	2.57 (2.04–3.23)	3.36 (2.49–4.52)	3.39 (2.52–4.56)	2.85 (2.44–3.32)	2.88 (2.47–3.36)	2.89 (1.97–4.25)	2.94 (2.00–4.32)

Post-exposure

Risk period 1 (≤ 21 d)	1.37 (1.02–1.83)	1.37 (1.02–1.83)	1.57 (1.17–2.09)	1.53 (1.15–2.05)	1.61 (1.06–2.45)	1.59 (1.05–2.42)	1.33 (1.06–1.66)	1.29 (1.04–1.62)	1.45 (0.85–2.48)	1.43 (0.84–2.44)

Risk period 2 (22 to 60 d)	0.79 (0.59–1.06)	0.79 (0.59–1.05)	0.65 (0.46–0.91)	0.64 (0.46–0.89)	1.12 (0.76–1.63)	1.10 (0.75–1.62)	0.90 (0.74–1.11)	0.88 (0.72–1.08)	0.41 (0.19–0.86)	0.40 (0.19–0.85)

Note: CI = confidence interval, IRR = incidence rate ratio, ref = reference category, XL = modified-release formula.
↵* See the Methods and Figure 1 for details about the periods.
↵† Adjusted for age and development of atrial flutter/fibrillation.